Clinical Trial Update: Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluated the combination of talazoparib and axitinib for previously treated advanced renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Unresectable Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)
• Talzenna (talazoparib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Kidney Cancer, Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED